{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:45:47Z","timestamp":1762505147412},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2006,6,22]],"date-time":"2006-06-22T00:00:00Z","timestamp":1150934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s00228-006-0156-5","type":"journal-article","created":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T12:34:57Z","timestamp":1150893297000},"page":"621-625","source":"Crossref","is-referenced-by-count":21,"title":["Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4"],"prefix":"10.1007","volume":"62","author":[{"given":"Ylva","family":"B\u00f6ttiger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,6,22]]},"reference":[{"issue":"6","key":"156_CR1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN Wildt de","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokin 37(6):485\u2013505","journal-title":"Clin Pharmacokin"},{"issue":"1","key":"156_CR2","first-page":"414","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414\u2013423","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 2","key":"156_CR3","first-page":"27","volume":"4","author":"A Walan","year":"1989","unstructured":"Walan A (1989) Clinical experience with omeprazole: assessment of efficacy and safety. J Gastroenterol Hepatol 4(Suppl 2):27\u201333","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"156_CR4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007691-199007000-00020","volume":"12","author":"T Andersson","year":"1990","unstructured":"Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12(4):415\u2013416","journal-title":"Ther Drug Monit"},{"issue":"6","key":"156_CR5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00008571-199512000-00004","volume":"5","author":"M Chang","year":"1995","unstructured":"Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5(6):358\u2013363","journal-title":"Pharmacogenetics"},{"key":"156_CR6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2125.1993.tb00410.x","volume":"36","author":"T Andersson","year":"1993","unstructured":"Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA et al (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521\u2013530","journal-title":"Br J Clin Pharmacol"},{"key":"156_CR7","unstructured":"B\u00f6ttiger Y (2000) Metabolic drug interactions in man\u2014methodological aspects on in vivo studies. Dissertation, Karolinska Institutet, Stockholm"},{"issue":"4","key":"156_CR8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0009-9236(97)90116-8","volume":"62","author":"Y B\u00f6ttiger","year":"1997","unstructured":"B\u00f6ttiger Y, Tybring G, Gotharson E, Bertilsson L (1997) Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 62(4):384\u2013391","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"156_CR9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1365-2125.1997.00630.x","volume":"44","author":"L Bertilsson","year":"1997","unstructured":"Bertilsson L, Tybring G, Widen J, Chang M, Tomson T (1997) Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol 44(2):186\u2013189","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"156_CR10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2125.1999.00865.x","volume":"47","author":"N Brynne","year":"1999","unstructured":"Brynne N, Bottiger Y, Hallen B, Bertilsson L (1999) Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. Br J Clin Pharmacol 47(2):145\u2013150","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"156_CR11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9236(03)00050-X","volume":"73","author":"M Christensen","year":"2003","unstructured":"Christensen M, Andersson K, Dal\u00e9n P, Mirghani RA, Muirhead GJ, Nordmark A et al (2003) The Karolinska cocktail for phenotyping of five cytochrome P450 enzymes. Clin Pharmacol Ther 73(6):517\u2013528","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"156_CR12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/clpt.1992.38","volume":"51","author":"L Bertilsson","year":"1992","unstructured":"Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM et al (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin [published erratum appears in Clin Pharmacol Ther 55(6):648]. Clin Pharmacol Ther 51(4):388\u2013397","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"156_CR13","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/hep.510230628","volume":"23","author":"KL Rost","year":"1996","unstructured":"Rost KL, Roots I (1996) Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 23(6):1491\u20131497","journal-title":"Hepatology"},{"issue":"2","key":"156_CR14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0009-9236(97)90060-6","volume":"62","author":"G Tybring","year":"1997","unstructured":"Tybring G, Bottiger Y, Widen J, Bertilsson L (1997) Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 62(2):129\u2013137","journal-title":"Clin Pharmacol Ther"},{"key":"156_CR15","doi-asserted-by":"crossref","unstructured":"Gonzalez HM, Romero EM, Aaron Peregrina A, Chavez TJ, Escobar-Islas E, Lozano F, et al (2003) CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. J Clin Pharmacol 43:1211\u20131215","DOI":"10.1177\/0091270003258170"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0156-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0156-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0156-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:30Z","timestamp":1558702290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0156-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,22]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0156-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,22]]}}}